Solasia Pharma K.K. (TYO:4597)
26.00
+2.00 (8.33%)
May 29, 2026, 3:30 PM JST
Solasia Pharma K.K. Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,569 | 1,387 | 886 | 728 | 803 | 714 |
Cash & Short-Term Investments | 1,569 | 1,387 | 886 | 728 | 803 | 714 |
Cash Growth | 47.32% | 56.55% | 21.70% | -9.34% | 12.46% | -75.91% |
Receivables | 19 | 374 | 232 | 67 | 572 | 126 |
Inventory | 111 | 112 | 128 | 122 | 14 | - |
Prepaid Expenses | - | 15 | 17 | 57 | 43 | 48 |
Other Current Assets | 17 | 2 | 3 | 2 | 3 | 6 |
Total Current Assets | 1,716 | 1,890 | 1,266 | 976 | 1,435 | 894 |
Property, Plant & Equipment | 104 | 113 | 47 | 81 | 63 | 120 |
Long-Term Investments | 170 | 141 | 47 | 52 | 60 | 49 |
Other Intangible Assets | - | - | - | 1,117 | 1,570 | 2,079 |
Other Long-Term Assets | 2 | 1 | 2 | 3 | 6 | 2 |
Total Assets | 1,992 | 2,145 | 1,362 | 2,229 | 3,134 | 3,144 |
Accounts Payable | 123 | 229 | 121 | 213 | 332 | 386 |
Accrued Expenses | - | 37 | 37 | 34 | 26 | 36 |
Current Portion of Leases | 31 | 31 | 25 | 33 | 37 | 47 |
Other Current Liabilities | 60 | 15 | 10 | 13 | 12 | 20 |
Total Current Liabilities | 214 | 312 | 193 | 293 | 407 | 489 |
Long-Term Leases | 55 | 64 | - | 27 | - | 37 |
Long-Term Deferred Tax Liabilities | 2 | 5 | - | 22 | 53 | 18 |
Other Long-Term Liabilities | 13 | 12 | 13 | 12 | 12 | 13 |
Total Liabilities | 284 | 393 | 206 | 354 | 472 | 557 |
Common Stock | 967 | 836 | 2,211 | 1,596 | 1,436 | 2,110 |
Additional Paid-In Capital | 1,584 | 1,455 | 2,255 | 1,657 | 1,500 | 5,738 |
Retained Earnings | -828 | -521 | -3,277 | -1,336 | -223 | -5,204 |
Treasury Stock | -65 | -65 | -65 | -69 | -70 | -70 |
Comprehensive Income & Other | 50 | 47 | 32 | 27 | 19 | 13 |
Shareholders' Equity | 1,708 | 1,752 | 1,156 | 1,875 | 2,662 | 2,587 |
Total Liabilities & Equity | 1,992 | 2,145 | 1,362 | 2,229 | 3,134 | 3,144 |
Total Debt | 86 | 95 | 25 | 60 | 37 | 84 |
Net Cash (Debt) | 1,483 | 1,292 | 861 | 668 | 766 | 630 |
Net Cash Growth | 41.51% | 50.06% | 28.89% | -12.79% | 21.59% | -66.91% |
Net Cash Per Share | 5.93 | 5.44 | 4.33 | 3.97 | 5.04 | 4.84 |
Filing Date Shares Outstanding | 268.35 | 273.01 | 218.05 | 173.94 | 167.97 | 133.54 |
Total Common Shares Outstanding | 268.35 | 263.3 | 218.05 | 173.94 | 167.97 | 133.51 |
Working Capital | 1,502 | 1,578 | 1,073 | 683 | 1,028 | 405 |
Book Value Per Share | 6.36 | 6.65 | 5.30 | 10.78 | 15.85 | 19.38 |
Tangible Book Value | 1,708 | 1,752 | 1,156 | 758 | 1,092 | 508 |
Tangible Book Value Per Share | 6.36 | 6.65 | 5.30 | 4.36 | 6.50 | 3.81 |